Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 1c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance